Sanofi Fires New Round Of Infringement Claims

Law360, New York (June 20, 2007, 12:00 AM EDT) -- Just days after suing Sandoz Inc., Sanofi-Aventis U.S. LLC stepped up its efforts to fend off generics Monday and made Israeli giant Teva Pharmaceutical Industries Ltd. the newest target of its Eloxatin patent infringement accusations.

The newest case in New Jersey district court over the colorectal cancer treatment, an oxaliplatin solution, underscores the pressure on Sanofi to protect the popular drug's patents, as well as those for other blockbuster drugs like Ambien.

According to the complaint, Teva infringed Sanofi's 5,338,874 and 5,716,988 patents when it filed...
To view the full article, register now.